RET Fusion

Loading variant…

Molecular profile	Therapy	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
Lung Adenocarcinoma1
v::RET Fusion	Cabozantinib	Predictive	B	Supports Sensitivity Response	3	accepted	EID4847 RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with … (full text at CIViC) PMID 27825636 · Drilon et al., 2016 · Open in CIViC	civic
Lung Non-Small Cell Carcinoma8
v::RET Fusion	Alectinib	Predictive	C	Supports Sensitivity Response	3	accepted	EID4850 Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. 4 patients with metastatic RET-rearranged NSCLC were identified. 3 of 4 had receive… (full text at CIViC) PMID 27544060 ·

Molecular profile

Therapy

Type

Level

Direction · significance

Rating (1–5)

Status

Evidence

Source

Lung Adenocarcinoma1

v::RET Fusion

Cabozantinib

Predictive

Supports Sensitivity Response

accepted

EID4847

RET rearrangements are found in 1-2% of non-small-cell lung cancers. Cabozantinib is a multikinase inhibitor with activity against RET that produced a 10% overall response in unselected patients with … (full text at CIViC)

PMID 27825636 · Drilon et al., 2016 · Open in CIViC

civic

Lung Non-Small Cell Carcinoma8

v::RET Fusion

Alectinib

Predictive

Supports Sensitivity Response

accepted

EID4850

Alectinib is an anaplastic lymphoma kinase tyrosine kinase inhibitor (TKI) that also has anti-RET activity in vitro. 4 patients with metastatic RET-rearranged NSCLC were identified. 3 of 4 had receive… (full text at CIViC)

PMID 27544060 ·

Malignant Neoplasm1
v::RET Fusion	Selpercatinib	Predictive	D	Supports Sensitivity Response	3	submitted	EID6949 In a preclinical analysis, RET inhibitor LOXO-292 was active against RET-Fusion positive cell lines and xenograft models PMID 29912274 · Subbiah et al., 2018 · Open in CIViC	civic

Malignant Neoplasm1

v::RET Fusion

Selpercatinib

Predictive

Supports Sensitivity Response

submitted

EID6949

In a preclinical analysis, RET inhibitor LOXO-292 was active against RET-Fusion positive cell lines and xenograft models

PMID 29912274 · Subbiah et al., 2018 · Open in CIViC

civic

Malignant Thyroid Gland Neoplasm4
v::RET Fusion	Pralsetinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID11234 In a phase 1/2, open-label trial, 122 patients with RET-mutant medullary cancer and 20 with RET-fusion positive thyroid cancer were administered 400 mg daily oral pralsetinib. The overall response rat… (full text at CIViC) PMID 34118198 · Subbiah et al., 2021 · Open in CIViC	civic
v::RET Fusion	Selpercatinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID8852 In this phase 1/2 trial (NCT03157128), patients with RET altered thyroid cancers were enrolled to receive the highly selective RET inhibitor selpercatinib. Among 19 patients with previously treated RE… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC	civic
v::RET Fusion OR RET Mutation	Pralsetinib	Predictive	A	Supports Sensitivity Response	4	submitted	EID11267 In this multi-cohort, open-label, phase 1/2 study, 122 patients with RET-mutant medullary and 20 with RET fusion-positive thyroid cancers were started on pralsetinib dosed at 400 mg once daily. Overal… (full text at CIViC) PMID 34118198 · Subbiah et al., 2021 · Open in CIViC	civic
v::RET Fusion OR RET Mutation	Selpercatinib	Predictive	A	Supports Sensitivity Response	4	rejected	EID11268 In this phase 1/2 study, 55 patients with RET-mutant medullary thyroid cancer who had previously received vandetanib and/or cabozantinib, 88 patients with the same disease who had not previously recei… (full text at CIViC) PMID 32846061 · Wirth et al., 2020 · Open in CIViC	civic

Malignant Thyroid Gland Neoplasm4

v::RET Fusion

Pralsetinib

Predictive

Supports Sensitivity Response

accepted

EID11234

In a phase 1/2, open-label trial, 122 patients with RET-mutant medullary cancer and 20 with RET-fusion positive thyroid cancer were administered 400 mg daily oral pralsetinib. The overall response rat… (full text at CIViC)

PMID 34118198 · Subbiah et al., 2021 · Open in CIViC

civic

v::RET Fusion

Selpercatinib

Predictive

Supports Sensitivity Response

accepted

EID8852

In this phase 1/2 trial (NCT03157128), patients with RET altered thyroid cancers were enrolled to receive the highly selective RET inhibitor selpercatinib. Among 19 patients with previously treated RE… (full text at CIViC)

PMID 32846061 · Wirth et al., 2020 · Open in CIViC

civic

v::RET Fusion OR RET Mutation

Pralsetinib

Predictive

Supports Sensitivity Response

submitted

EID11267

In this multi-cohort, open-label, phase 1/2 study, 122 patients with RET-mutant medullary and 20 with RET fusion-positive thyroid cancers were started on pralsetinib dosed at 400 mg once daily. Overal… (full text at CIViC)

PMID 34118198 · Subbiah et al., 2021 · Open in CIViC

civic

v::RET Fusion OR RET Mutation

Selpercatinib

Predictive

Supports Sensitivity Response

rejected

EID11268

In this phase 1/2 study, 55 patients with RET-mutant medullary thyroid cancer who had previously received vandetanib and/or cabozantinib, 88 patients with the same disease who had not previously recei… (full text at CIViC)

PMID 32846061 · Wirth et al., 2020 · Open in CIViC

civic

Solid Neoplasm4
v::RET Fusion	Pralsetinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID11266 In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC) PMID 35962206 · Subbiah et al., 2022 · Open in CIViC	civic
v::RET Fusion	Selpercatinib	Predictive	B	Supports Sensitivity Response	3	submitted	EID12134 In this arm of the trial (LIBRETTO-001), the efficacy of selpercatinib was tested in 45 patients harbouring RET fusion-positive solid tumours (excluding lung or thyroid tumours). The objective respons… (full text at CIViC) PMID 36108661 · Subbiah et al., 2022 · Open in CIViC	civic
v::RET Fusion OR RET Mutation	Selpercatinib	Predictive	A	Supports Sensitivity Response	4	accepted	EID12056 As part of this trial, 27 pediatric patients (aged 2-20), harbouring, RET-mutant medullary thyroid cancer (MTC, n = 14), RET fusion-positive papillary thyroid cancer (RTC, n=10), or other tumour types… (full text at CIViC) Open in CIViC	civic
v::RET Fusion OR RET Mutation	Selpercatinib	Predictive	A	Supports Sensitivity Response	5	accepted	EID12708 In the phase 1/2 trial LIBRETTO-121 (NCT03899792), for patients 0.5-21 yrs old with advanced RET-altered solid tumors, dosing started at 92 mg/m2 twice a day of Selpercatinib. Patients had RET-mutant… (full text at CIViC) Open in CIViC	civic

Solid Neoplasm4

v::RET Fusion

Pralsetinib

Predictive

Supports Sensitivity Response

submitted

EID11266

In the phase 1/2 clinical trial NCT03037385, one arm assessed the therapeutic benefit of the selective RET inhibitor pralsetinib across a range RET fusion positive solid tumors, excluding NSCLC and th… (full text at CIViC)

PMID 35962206 · Subbiah et al., 2022 · Open in CIViC

civic

v::RET Fusion

Selpercatinib

Predictive

Supports Sensitivity Response

submitted

EID12134

In this arm of the trial (LIBRETTO-001), the efficacy of selpercatinib was tested in 45 patients harbouring RET fusion-positive solid tumours (excluding lung or thyroid tumours). The objective respons… (full text at CIViC)

PMID 36108661 · Subbiah et al., 2022 · Open in CIViC

civic

v::RET Fusion OR RET Mutation

Selpercatinib

Predictive

Supports Sensitivity Response

accepted

EID12056

As part of this trial, 27 pediatric patients (aged 2-20), harbouring, RET-mutant medullary thyroid cancer (MTC, n = 14), RET fusion-positive papillary thyroid cancer (RTC, n=10), or other tumour types… (full text at CIViC)

Open in CIViC

civic

v::RET Fusion OR RET Mutation

Selpercatinib

Predictive

Supports Sensitivity Response

accepted

EID12708

In the phase 1/2 trial LIBRETTO-121 (NCT03899792), for patients 0.5-21 yrs old with advanced RET-altered solid tumors, dosing started at 92 mg/m2 twice a day of Selpercatinib. Patients had RET-mutant… (full text at CIViC)

Open in CIViC

civic

Thyroid Gland Papillary Carcinoma1
v::RET Fusion	Selpercatinib	Predictive	B	Supports Sensitivity Response	4	accepted	EID7069 In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Among the 6 patients with RET-fusion positive papil… (full text at CIViC) Open in CIViC	civic

Thyroid Gland Papillary Carcinoma1

v::RET Fusion

Selpercatinib

Predictive

Supports Sensitivity Response

accepted

EID7069

In this phase 1 trial, patients with RET-fusion or mutation positive cancers were treated with the selective RET-inhibitor selpercatinib (LOXO-292). Among the 6 patients with RET-fusion positive papil… (full text at CIViC)

Open in CIViC

civic

Evidence by cancer (19 items)

Clinical significance (0)